Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of the American College of Cardiology

• Publication date

  2007-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JACC.2006.11.024PMID 17306703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring clinical changes in patients with heart failure: a comparison of methods.

  2005cited by this paper
• Are hematinic deficiencies the cause of anemia in chronic heart failure?

  2004cited by this paper
• Anemia in chronic heart failure: pathogenetic mechanisms.

  2004cited by this paper
• The prevalence and natural history of anaemia in an optimally treated heart failure population

  2004cited by this paper
• Anemia and Its Relationship to Clinical Outcome in Heart Failure

  2004cited by this paper
• Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial.

  2004cited by this paper
• Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.

  2003influential reference
• Comparison of quality of life measures in heart failure.

  2003cited by this paper
• Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure

  2003cited by this paper
• Effect of anemia on exercise tolerance in chronic heart failure in men.

  2003cited by this paper
• The prognostic importance of anemia in patients with heart failure.

  2003cited by this paper
• Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).

  2003cited by this paper
• Anaemia is an independent predictor of poor outcome in patients with chronic heart failure.

  2003cited by this paper
• Comparison of Quality of Life Measures in Heart Failure

  2003cited by this paper
• STAMINA-HFP (study of anemia in a heart failure population) registry: rationale, design, and patient characteristics

  2003cited by this paper
• Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

  2002cited by this paper
• Cardiac resynchronization in chronic heart failure.

  2002cited by this paper
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study

  2002cited by this paper
• The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.

  2001cited by this paper
• Development and characterization of novel erythropoiesis stimulating protein (NESP)

  2001cited by this paper
• The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.

  2000cited by this paper
• Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

  2000cited by this paper
• A Review of Quality-of-Life Evaluations in Patients with Congestive Heart Failure

  1999cited by this paper
• Determining Clinically Important Differences in Health Status Measures

  1999cited by this paper
• Effects of ACE Inhibitor Therapy on Quality of Life in Patients with Heart Failure

  1998cited by this paper
• Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death.

  1995cited by this paper
• Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.

  1993cited by this paper
• Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.

  1992cited by this paper
• Patients' self-assessment of their congestive heart failure : Content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire

  1987cited by this paper
• Exercise and the failing heart.

  1987cited by this paper

• Insuficiencia cardíaca

  2026cites this paper
• Pioneering therapies for post-infarction angiogenesis: Insight into molecular mechanisms and preclinical studies.

  2023cites this paper
• The treatment of chronic anemia in heart failure: a global approach

  2023cites this paper
• Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz

  2022cites this paper
• CME Zertifizierte Fortbildung Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2)

  2022cites this paper
• АНЕМИЯ У ЛИЦ ПОЖИЛОГО ВОЗРАСТА В ПРАКТИКЕ ТЕРАПЕВТА: СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ

  2021cites this paper
• Iron Deficiency: A New Target for Patients With Heart Failure

  2021cites this paper
• ANEMIA IN ELDERLY PATIENTS IN GENERAL MEDICAL PRACTICE: CURRENT APPROACHES TO DIAGNOSIS AND TREATMENT

  2021cites this paper
• Anemia and Management of Heart Failure Patients.

  2021cites this paper
• Intravenous iron in heart failure and chronic kidney disease.

  2021cites this paper
• Erythropoietin role in the therapeutic management of heart failure patients with anemia

  2020cites this paper
• Gamma-Aminobutyric Acid Increases Erythropoietin by Activation of Citrate Cycle and Stimulation of Hypoxia-Inducible Factors Expression in Rats

  2020cites this paper
• Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials

  2020cites this paper
• Developmental and regenerative paradigms of cilia regulated hedgehog signaling.

  2020cites this paper
• Hartfalen

  2020cites this paper
• Intravenous iron in heart failure and chronic kidney disease.

  2020cites this paper
• Anaemia in heart failure patients: the prevalence of haematinic deficiencies and the role of ACE inhibitors and aspirin doses as risk factors

  2019cites this paper
• Role of iron metabolism in heart failure: From iron deficiency to iron overload.

  2019cites this paper
• Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: Comorbidity in Heart Failure

  2019cites this paper
• Iron deficiency in heart failure

  2018cites this paper
• Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies

  2018cites this paper
• EPO Derivative ARA290 Attenuates Early Renal Allograft Injury in Rats by Targeting NF-κB Pathway.

  2018cites this paper
• [Selection of Optimal Therapy at Correction of the Anemic Syndrome in Patients With Chronic Heart Failure].

  2018cites this paper
• HUBUNGAN ANEMIA DENGAN KUALITAS HIDUP PASIEN GAGAL JANTUNG KRONIK

  2018cites this paper
• Iron Deficiency in Heart Failure: to Treat or Not to Treat?

  2018cites this paper
• DEPTH Anemia and Iron Deficiency in Heart Failure Current Concepts and Emerging Therapies

  2018cites this paper
• Ferropenia sin anemia, más que un hallazgo de laboratorio

  2018cites this paper
• Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology

  2018cites this paper
• La sindrome anemica cardio-renale. Terza parte: Terapia

  2018cites this paper
• Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy

  2017cites this paper
• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

  2017cites this paper
• Comorbidities in Heart Failure.

  2017cites this paper
• The Cardiovascular Protective Effects of Erythropoietin Stimulating Agents

  2017cites this paper
• Anemia and coronary artery disease: pathophysiology, prognosis, and treatment

  2017cites this paper
• Anemia and Iron Deficiency in Heart Failure — Clinical Update

  2017cites this paper
• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

  2017cites this paper
• Iron deficiency and anemia in heart failure.

  2017cites this paper
• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

  2017cites this paper
• Iron substitution in the treatment of chronic heart failure.

  2017cites this paper
• Carbamylated erythropoietin enhances mice ventilatory responses to changes in O2 but not CO2 levels.

  2016cites this paper
• Are erythropoiesis-stimulating agents beneficial for anemia in chronic heart failure patients?

  2016cites this paper
• Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis

  2016cites this paper
• Managing anemia in patients with chronic heart failure ; Is there a new pathway ?

  2016cites this paper
• Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure.

  2016cites this paper
• The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.

  2016cites this paper
• Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia

  2016cites this paper
• Maksimaalisen hapenottokyvyn arviointi bioimpedanssianalyysin ja sen antamien muuttujien avulla

  2015cites this paper
• Iron deficiency and cardiovascular disease

  2015cites this paper
• Reply: Cardiovascular function and exercise capacity in patients with colorectal cancer: does anticancer therapy matter?

  2015cites this paper
• Effects of Blood Transfusion on Exercise Capacity in Thalassemia Major Patients

  2015cites this paper
• Use of Erythropoiesis-Stimulating Agents in the Treatment of Anemia in Patients With Systolic Heart Failure

  2015influential citation
• The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions

  2014cites this paper
• Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia

  2014cites this paper
• Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease

  2014cites this paper
• Anemia e deficiência de ferro na insuficiência cardíaca

  2014cites this paper
• [Erythropoiesis-stimulating agents in congestive heart failure patients].

  2014cites this paper
• Erythropoietin and the heart: physiological effects and the therapeutic perspective.

  2014cites this paper
• Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.

  2014cites this paper
• Clinical outcomes of erythropoietin use in heart failure patients with anemia of chronic kidney disease.

  2014cites this paper
• Side Effects of Cytokines Approved for Therapy

  2014cites this paper
• Anemia and iron deficiency in heart failure.

  2014cites this paper
• Erythropoietin Therapy for Heart Failure

  2014cites this paper
• Distinguishing Anemia and Iron Deficiency of Heart Failure: Signal for Severity of Disease or Unmet Therapeutic Need?

  2014cites this paper
• Anemia and iron deficiency in heart failure.

  2014cites this paper
• Treatment of Anemia in Patients With Heart Disease

  2013cites this paper
• New therapeutic options in heart failure. What's on the horizon? An overview.

  2013cites this paper
• Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

  2013cites this paper
• Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians

  2013influential citation
• Eficacia de los estimulantes de la eritropoyesis para el manejo de la anemia asociada al sindrome cardio-renal en el paciente adulto

  2013influential citation
• Herzinsuffizienz und Anämie

  2013cites this paper
• Anemia associated with chronic heart failure: current concepts

  2013cites this paper
• Erythropoietin and heart failure: the end of a promise?

  2013cites this paper
• Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the heart failure with preserved ejection fraction (HFPEF) anemia trial.

  2013cites this paper
• Treatment of Anemia in Patients With Heart Disease

  2013influential citation
• Cardiorenal Syndrome Revisited

  2013cites this paper
• Cardiac Mortality-Risk Assessment Improved by Evaluation of Hemoglobin Level in Combination with Kidney Function in the Patients with Systolic Heart Failure: A Cohort Study

  2013cites this paper
• [Heart failure and anemia].

  2013cites this paper
• Treatment of anemia with darbepoetin alfa in systolic heart failure.

  2013cites this paper
• Kidney function and congestive heart failure. The Norwegian perspective.

  2013cites this paper
• Erythropoietin Receptor (EpoR) Agonism Is Used to Treat a Wide Range of Disease

  2013cites this paper
• The Role of Treatment for Anemia as a Therapeutic Target in the Management of Chronic Heart Failure: Insights After RED-HF

  2013cites this paper
• Erythropoietin in cardiac disease: effective or harmful?

  2013cites this paper
• Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists?

  2012cites this paper
• OCENA PRZYDATNOŚCI OZNACZENIA WSKAŹNIKA ROZKŁADU OBJĘTOŚCI KRWINEK CZERWONYCH (RDW) W OKREŚLENIU ROKOWANIA U PACJENTÓW Z PRZEWLEKŁĄ NIEWYDOLNOŚCIĄ SERCA

  2012cites this paper
• Health-related quality of life and anemia in hospitalized patients with heart failure.

  2012cites this paper
• Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry.

  2012cites this paper
• Tratamiento de la anemia en el síndrome cardiorrenal

  2012cites this paper
• Tratamiento de la anemia en el síndrome cardiorrenal

  2012cites this paper
• Myocardial iron homeostasis in advanced chronic heart failure patients.

  2012cites this paper
• Anemia and Iron Deficiency in Heart Failure

  2012cites this paper
• Prevalence and Treatment of Iron Deficiency Anemia in Patients with Chronic Heart Failure

  2012cites this paper
• Erythropoietin: a future therapy for failing hearts?

  2012cites this paper
• In vivo cardiac anatomical and functional effects of wheel running in mice by magnetic resonance imaging

  2012cites this paper
• Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives

  2012cites this paper
• An integrated approach to outcome evaluation : incorporating patient reported outcomes in heart failure

  2012cites this paper
• Vliv vstupní anémie na dlouhodobou mortalitu pacientů hospitalizovaných pro akutní srdeční selhání

  2012cites this paper
• Anemia in chronic heart failure: Can we treat? What to treat?

  2012cites this paper
• Red blood cell transfusions in children awaiting heart transplantation

  2011cites this paper
• Erythropoiesis-stimulating agents and heart failure.

  2011cites this paper
• Clinical perspective: iron replacement therapy in chronic heart failure

  2011cites this paper